The session is a dedicated platform for CEO Tore Duvold to address questions regarding the Company's recent technical milestones, clinical evidence, and the transition toward commercial partnerships. As we finalize Generation 3.0 and execute our partner-led strategy, we remain focused on replacing estimation with evidence in the global fertility diagnostics market.

Webcast Details:

• Date: Thursday, 26 March 2026.
• Time: 12:00 CET.
• Language: English and Swedish.
• Join: https://teams.microsoft.com/meet/33135525200798?p=PzGVIFSr0gwokxA4Ly

Meeting ID: 331 355 252 007 98

Passcode: ye2zF3Qz

• Final Call for Questions: To ensure a productive and focused session, participants are invited to submit questions by the end of today, Wednesday, 25 March 2026.

• Email questions to: info@spermosens.com.

Spermosens intends to establish these Q&A sessions as a recurring event to further enhance transparency and investor dialogue.

For further information, please contact:

Tore Duvold, CEO

Email: info@spermosens.com

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com